ORAMED PHARMACEUTICALS INC.ORMPEarnings & Financial Report
Oramed Pharmaceuticals Inc., is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
Revenue
$0
Gross Profit
$0
Operating Profit
$-2.5M
Net Profit
$13.3M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$0.31
ORAMED PHARMACEUTICALS INC. Q2 FY2025 Financial Summary
ORAMED PHARMACEUTICALS INC. reported revenue of $0 for Q2 FY2025, with a net profit of $13.3M (up 44.2% YoY) (N/A margin). Cost of goods sold was $0, operating expenses totaled $2.5M.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $13.3M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q2 FY2025 |
ORAMED PHARMACEUTICALS INC. Annual Revenue by Year
ORAMED PHARMACEUTICALS INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.0M).
| Year | Annual Revenue |
|---|---|
| 2025 | $2.0M |
| 2023 | $1.3M |
| 2022 | $2.7M |
ORAMED PHARMACEUTICALS INC. Quarterly Revenue & Net Profit History
ORAMED PHARMACEUTICALS INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $10.0M | N/A |
| Q3 FY2025 | $0 | — | $48.4M | N/A |
| Q2 FY2025 | $0 | — | $13.3M | N/A |
| Q1 FY2025 | $2.0M | — | $-7.6M | -382.1% |
| Q4 FY2023 | $0 | — | $12.9M | N/A |
| Q3 FY2023 | $0 | — | $-3.2M | N/A |
| Q2 FY2023 | $674.0K | +0.0% | $-1.2M | -177.2% |
| Q1 FY2023 | $666.0K | +0.0% | $-3.4M | -509.8% |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $666000 | $674000 | $0 | $0 | $2.0M | $0 | $0 | $0 |
| YoY Growth | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $159.8M | $156.3M | $230.9M | $220.6M | $147.5M | $161.7M | $220.5M | $230.9M |
| Liabilities | $8.8M | $4.8M | $81.8M | $56.7M | $6.7M | $7.2M | $17.2M | $31.1M |
| Equity | $151.0M | $151.5M | $149.1M | $163.8M | $140.8M | $154.5M | $203.3M | $199.7M |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.5M | $-2.6M | $-694000 | $-1.4M | $-3.5M | $-3.5M | $-1.6M | $-466000 |